EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Decoding PACAP signaling: Splice variants, pathways and designer drugs

Zoe Tasma iD, Debbie L Hay iD

Cephalalgia · 2025

DOI: 10.1177/03331024251363560 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cephalalgia, 2025. Verfasst von Zoe Tasma und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, The University of Otago, Dunedin, New Zealand. Hauptthemen laut MEDLINE: Pituitary Adenylate Cyclase-Activating Polypeptide, Signal Transduction, Designer Drugs, Migraine Disorders. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 216 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: University of Otago.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The neuropeptides pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) play roles in vasodilation, the immune response and neuronal signaling, with recent links to headache disorders. This association has resulted in considerable interest in targeting this family of peptides and their receptors for drug development, and, notably, an anti-PACAP antibody has reported clinical efficacy in reducing migraine frequency. The PACAP/VIP ligands act at G protein-coupled receptors (GPCRs). PAC 1 , VPAC 1 and VPAC 2 are the officially-recognized canonical receptors. Each of these has the potential to generate receptor variants through exon splicing. These variants may exhibit altered function, significantly increasing the diversity of PACAP-responsive receptors. In addition to these canonical receptors, PACAP is proposed to activate other unrelated receptors, GPR55 and MRGPRX2. Altogether, any of these canonical and proposed receptors may mediate the biological actions of PACAP, including migraine-relevant behaviors. However, we have a limited understanding of how these receptors function, such as their capacity to activate downstream signaling, the cellular and subcellular location of that signaling, and whether accessory protein interactions may alter these responses, especially in migraine-relevant contexts. The complex nature of the PACAP/VIP system therefore provides not only numerous considerations for target design and validation, but also unique opportunities for “designer” drugs. This narrative review provides an overview of the complex PACAP/VIP system, exploring peptide, receptor and downstream signaling behaviors that may be potential targets for the treatment of headache disorders and beyond.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pituitary Adenylate Cyclase-Activating PolypeptideSignal TransductionDesigner DrugsMigraine DisordersHumansAnimalsReceptors, G-Protein-Coupled

Stichwörter der Autor:innen

G protein-coupled receptorMRGPACAPVIPmigraineneuropeptide

Substanzen

Pituitary Adenylate Cyclase-Activating PolypeptideDesigner DrugsReceptors, G-Protein-Coupled

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, The University of Otago, Dunedin, New Zealand.

ORCID-Profile: Zoe Tasma, Debbie L Hay

Förderung

  • University of Otago

Zitieren

APA

Tasma, Z., & Hay, D. L. (2025). Decoding PACAP signaling: Splice variants, pathways and designer drugs. Cephalalgia. https://doi.org/10.1177/03331024251363560

Vancouver

Tasma Z, Hay DL. Decoding PACAP signaling: Splice variants, pathways and designer drugs. Cephalalgia. 2025. doi:10.1177/03331024251363560

BibTeX
@article{Tasma2025,
  author = {Tasma, Zoe and Hay, Debbie L},
  title = {Decoding PACAP signaling: Splice variants, pathways and designer drugs},
  journal = {Cephalalgia},
  year = {2025},
  doi = {10.1177/03331024251363560}
}
Kostenlos starten →